Chronic Erythropoietin Treatment Limits Infarct-size in the Myocardium in Vitro
- 1 October 2005
- journal article
- research article
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 19 (5) , 333-336
Abstract
It has been well established that erythropoietin (EPO) can limit myocardial ischemia/reperfusion injury in a variety of acute settings. However, despite EPO being used chronically to treat anemia the infarct limiting effects of long term treatment (chronic) have never been fully investigated. In this study we examined the effects of a 3 week treatment of EPO (5,000 IU/Kg) in male Sprague Dawley rats in limiting myocardial infarction after 35 min ischemia and 2 h reperfusion in an in vitro isolated heart perfusion model. Treating the animals ‘once a week’ failed to limit infarct size significantly compared to a saline control (54.1% ± 3.5 v 52.3% ± 4.4), whereas a ‘3 times a week’ regime succeeded in significantly reducing infarct size (36.2% ± 3.2 v 52.3% ± 4.4, p < 0.05). To demonstrate that the effect was not due to improved oxygen supply caused by a raised hematocrit level, we also administered EPO 24 h prior to ischemia/reperfusion. This treatment again reduced infarct size compared to a saline control (39.9% ± 4.4 v 58.4% ± 5.0, p < 0.05). To examine the mechanism of protection we used the PI3K inhibitor wortmannin and the nitric oxide synthase inhibitor L-NAME to try to abrogate EPO mediated protection. Where wortmannin failed to block the effects of EPO (31.7% ± 6.0 v 36.2% ± 3.2), L-NAME did abrogate protection (51.6% ± 5.6 v 36.2% ± 3.2, p < 0.05). We demonstrate that chronic EPO treatment limits infarct size and that it does so in a nitric oxide dependent manner.Keywords
This publication has 23 references indexed in Scilit:
- Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivoBasic Research in Cardiology, 2005
- Mechanisms of erythropoietin‐mediated cardioprotection during ischemia‐reperfusion injury: role of protein kinase C and phosphatidylinositol 3‐kinase signalingThe FASEB Journal, 2005
- Heart mitochondrial nitric oxide synthase is upregulated in male rats exposed to high altitude (4,340 m)American Journal of Physiology-Heart and Circulatory Physiology, 2005
- PHLPP: A Phosphatase that Directly Dephosphorylates Akt, Promotes Apoptosis, and Suppresses Tumor GrowthMolecular Cell, 2005
- Nitric oxide donors protect murine myocardium against infarction via modulation of mitochondrial permeability transitionAmerican Journal of Physiology-Heart and Circulatory Physiology, 2005
- Erythropoietin Just Before Reperfusion Reduces Both Lethal Arrhythmias and Infarct Size via the Phosphatidylinositol-3 Kinase-Dependent Pathway in Canine HeartsCardiovascular Drugs and Therapy, 2005
- The nonerythropoietic asialoerythropoietin protects against neonatal hypoxia‐ischemia as potently as erythropoietinJournal of Neurochemistry, 2004
- New directions for protecting the heart against ischaemia–reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathwayCardiovascular Research, 2004
- Nitric Oxide Mediates the Antiapoptotic Effect of Insulin in Myocardial Ischemia-ReperfusionCirculation, 2002
- Exposure of endothelial cells to recombinant human erythropoietin induces nitric oxide synthase activityKidney International, 2000